Dilek Celik

Dilek Celik

Auto-generated profile, based on publicly available information

Dilek Celik

Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
DCDilek Celik
Dilek Celik
MCManuela Campisi
Manuela Campisi
LCLuana Cannella
Luana Cannella
Sofia PavanelloSofia Pavanello
Sofia Pavanello
Sarcopenia, a musculoskeletal disease characterized by the progressive loss of skeletal muscle mass, strength, and physical performance, presents significant challenges to global public health due to its adverse effects on mobility, morbidity, mortality, and healthcare costs. This comprehensive review explores the intricate connections between sarcopenia and low birth weight (LBW), emphasizing the developmental origins of health and disease (DOHaD) hypothesis, inflammatory processes (inflammaging), mitochondrial dysfunction, circadian rhythm disruptions, epigenetic mechanisms, and genetic variations revealed through genome‐wide studies (GWAS). A systematic search strategy was developed using PubMed to identify relevant English‐language publications on sarcopenia, LBW, DOHaD, inflammaging, mitochondrial dysfunction, circadian disruption, epigenetic mechanisms, and GWAS. The publications consist of 46.2% reviews, 21.2% cohort studies, 4.8% systematic reviews, 1.9% cross‐sectional studies, 13.4% animal studies, 4.8% genome‐wide studies, 5.8% epigenome‐wide studies, and 1.9% book chapters. The review identified key factors contributing to sarcopenia development, including the DOHaD hypothesis, LBW impact on muscle mass, inflammaging, mitochondrial dysfunction, the influence of clock genes, the role of epigenetic mechanisms, and genetic variations revealed through GWAS. The DOHaD theory suggests that LBW induces epigenetic alterations during foetal development, impacting long‐term health outcomes, including the early onset of sarcopenia. LBW correlates with reduced muscle mass, grip strength, and lean body mass in adulthood, increasing the risk of sarcopenia. Chronic inflammation (inflammaging) and mitochondrial dysfunction contribute to sarcopenia, with LBW linked to increased oxidative stress and dysfunction. Disrupted circadian rhythms, regulated by genes such as BMAL1 and CLOCK, are associated with both LBW and sarcopenia, impacting lipid metabolism, muscle mass, and the ageing process. Early‐life exposures, including LBW, induce epigenetic modifications like DNA methylation (DNAm) and histone changes, playing a pivotal role in sarcopenia development. Genome‐wide studies have identified candidate genes and variants associated with lean body mass, muscle weakness, and sarcopenia, providing insights into genetic factors contributing to the disorder. LBW emerges as a potential early predictor of sarcopenia development, reflecting the impact of intrauterine exposures on long‐term health outcomes. Understanding the complex interplay between LBW with inflammaging, mitochondrial dysfunction, circadian disruption, and epigenetic factors is essential for elucidating the pathogenesis of sarcopenia and developing targeted interventions. Future research on GWAS and the underlying mechanisms of LBW‐associated sarcopenia is warranted to inform preventive strategies and improve public health outcomes.

18 July 2025 in Internal and Emergency Medicine
Verified
Journal Article
Open access
DCDilek Celik
Dilek Celik
CACheima Amrouch
Cheima Amrouch
SJSøren Paaske Johnsen
Søren Paaske Johnsen
GLGregory Y H Lip
Gregory Y H Lip
DVDavide Liborio Vetrano
Davide Liborio Vetrano
ACAFFIRMO Consortium
AFFIRMO Consortium
Managing atrial fibrillation (AF) patients with multiple comorbidities and complex medications is challenging. This study aimed to identify different patient profiles of AF based on comorbidities and medicines combinations and to explore their associations with the risk of adverse outcomes. This cohort study included patients with AF from the anticoagulant outpatient clinic at a hospital in Italy, undergoing follow-ups every 6 months. Comorbidity and medication patterns were identified using latent class analysis. Cox regression was used to explore associations with thromboembolism, major bleeding, falls, and death—separately and composite. A total of 633 patients with AF (mean age 80.5 ± 6.9 years, 52.5% women) treated with direct oral anticoagulants were followed for a median of 24.2 (IQR 12.1–35.5) months. Four patterns were identified: unspecific pattern (39.0%), diabetes and liver pattern (14.8%), neurocognitive and psychiatric pattern (14.1%), and musculoskeletal, immunologic and dermatologic pattern (32.1%). After adjustments, the neurocognitive and psychiatric pattern was associated with a higher risk of the composite outcome (hazard ratio [HR] [95% CI]: 1.75 [1.56–3.82]), thromboembolism (HR: 3.04 [1.28–7.22]) and major bleeding (HR: 2.55 [1.05–6.22]) compared to the non-specific pattern. The musculoskeletal, immunologic, and dermatologic pattern was also associated with a higher bleeding risk (HR: 2.21 [1.05–4.65]). Stratified analyses showed that these links were stronger in patients without cancer, and there was significant interaction in bleeding risk based on cancer status ( p = 0.014). Anticoagulated AF patients with the neurocognitive and psychiatric profile are at higher risk, emphasizing the need for holistic AF management.

23 June 2026 in GeroScience
Verified
Journal Article
Open access
DCDilek Celik
Dilek Celik
AOAlice Margherita Ornago
Alice Margherita Ornago
FTFederico Triolo
Federico Triolo
APAnna Picca
Anna Picca
RCRiccardo Calvani
Riccardo Calvani
DVDavide Liborio Vetrano
Davide Liborio Vetrano
The long-term impact of atrial fibrillation (AF) and systemic inflammation on muscle health and, hence, functional decline remains unclear. This study investigates the link between AF and longitudinal trajectories of muscle mass and strength, considering the role played by systemic inflammation. Data were obtained from 2048 participants (≥ 60 years) in the Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), followed for 12 years. Muscle mass and strength were assessed using calf circumference, handgrip strength, and chair stand test. Inflammatory marker interleukin-6 (IL-6) and the stress-response mediator growth differentiation factor-15 (GDF-15) were measured at baseline. Linear mixed models examined the longitudinal changes in muscle outcomes according to AF status and the combination of AF status with inflammatory markers. Participants with AF experienced a steeper increase in the duration of the chair stand test (β = 1.49; 95% CI: 0.82 to 2.16). High levels of GDF-15 amplified declines in muscle mass (β = − 0.12; 95% CI: − 0.20 to − 0.05) and chair stand test performance (β = 2.48; 95% CI: 1.66 to 3.30) in individuals with AF. Participants with AF and high IL-6 levels also experienced an accelerated decline of calf circumference (β = − 0.12; 95% CI: − 0.19 to − 0.05) and chair stand test performance (β = 2.20; 95% CI: 1.39 to 3.01). AF is associated with a steeper decline in muscle mass and strength over time, exacerbated by elevated inflammatory biomarkers, underscoring the importance of systemic inflammation in AF-related functional decline.